Not all eplet mismatches are created equal - A cohort study illustrating implications to long-term graft outcomes

Area of Science:

• Nephrology
• Immunology
• Transplantation Science

Background:

• Kidney transplant graft survival is crucial for patient outcomes.
• Eplet mismatches (EMM) are increasingly recognized as critical factors influencing transplant success.
• Current compatibility strategies require refinement for personalized patient care.

Purpose of the Study:

• To assess the impact of various eplet-compatibility strategies on death-censored graft failure (DCGF).
• To evaluate how recipient, donor, and transplant characteristics influence DCGF across different categories of EMM.
• To inform personalized care by identifying high-risk eplets and patient profiles.

Main Methods:

• Analysis of the Scientific Registry of Transplant Recipients database.
• Calculation of adjusted hazard ratios (HR) for DCGF based on ascending categories of EMM.
• Evaluation of different eplet-compatibility strategies, including complete epitype, antibody-verified epitype, and class II eplets.

Main Results:

• The Epi15 strategy demonstrated better differentiation of DCGF risk per EMM.
• Specific recipient (<25 years) and donor (>55 years) characteristics, along with certain immunosuppression regimens, showed higher HR for DCGF.
• High-risk EMM categories provided better differentiation of DCGF probabilities, suggesting targeted compatibility benefits.

Conclusions:

• Eplet compatibility, particularly focusing on high-risk eplets, is essential for predicting and improving kidney transplant outcomes.
• Personalized allocation schemes prioritizing compatibility on high-risk eplets may benefit recipients at greater risk of graft failure.
• Further research into eplet-based matching can enhance long-term graft survival and patient quality of life.